NKGN — Nkgen Biotech Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: NKGen Biotech Secures Additional Financing of $5 Mln To Continue Advancing Its Clinical Programs
Brief: Nkgen Biotech Presents Additional Phase 1 Clinical Trial Data In Alzheimer’S Disease At The Tau2024 Global Conference
Brief: Nkgen Biotech's Sangwoo Park Notified Board He Will Step Down As Chairperson
Brief: NKGen Biotech Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq On Mar 11
Brief: Nkgen Biotech Says It Entered Into Amendment To Forward Purchase Agreement, Dated As Of Sept 26, 2023
Brief: NKGen Bio Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01
Brief: NKGen Biotech Says Co And Seller Entered Into Amendment To Forward Purchase Agreement
Brief: NKGen Biotech Announces Clearance Of Clinical Trial Application By Health Canada For SNK01 NK Cell Therapy
Brief: Nkgen Biotech Announces FDA Clearance Of Investigational New Drug Application To Treat Alzheimer’S Disease
Brief: NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Brief: NKGen Biotech Presents Interim Phase I Trial Data